Development
ASCO: BMS's CELMoD mezigdomide reduces progression risk by 52% in Phase III multiple myeloma trial
Bristol Myers Squibb (NYSE: BMY) reported that mezigdomide, its oral cereblon E3 ligase modulator (CELMoD), cut the risk of disease progression or death by...
Gilead terminates early study for BTLA agonist in rheumatoid arthritis due to efficacy concerns
Gilead Sciences (Foster City, California, USA) has terminated its Phase Ib clinical trial of GS-0272, a selective B and T Lymphocyte Attenuator (BTLA)...
ASCO: D3 Bio shows off elisrasib's 78% response rate in first-line KRAS G12C lung cancer
D3 Bio reported response rates above 78% for elisrasib in previously untreated KRAS G12C–mutant non-small cell lung cancer at ASCO 2026, a result that, if...
ASCO: Eli Lilly's selpercatinib reduces disease recurrence risk by 83% in Phase III for RET fusion-positive lung cancer
Eli Lilly (NYSE: LLY) reported that selpercatinib (Retevmo) cut the risk of disease recurrence or death by 83% versus placebo in early-stage RET...
ASCO: CSPC's HER2 BsAb achieves 62.4% CR in Phase III breast cancer trial
CSPC Pharmaceutical Group (HKEX: 1093) reported Phase III data showing that anbenitamab (Ennituo), its HER2 bispecific antibody co-developed with Jiangsu...
ASCO: J&J's Rybrevant Faspro shows 42% response rate in pivotal head and neck cancer study
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase Ib/II data showing that subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) produced a...
Johnson & Johnson's apalutamide plus hormone therapy reduces metastasis risk in Phase III prostate cancer trial
Johnson & Johnson reported Phase III data on Saturday showing that apalutamide (Erleada) added to hormone therapy before and after localized prostate cancer...
Akeso's ivonescimab beats tislelizumab in Phase III squamous NSCLC overall survival trial
Akeso (HKEX: 9926.HK) reported on Saturday that ivonescimab, its PD-1/VEGF bispecific antibody, cut the risk of death by 34% compared with a PD-1 inhibitor...
ASCO: Dizal's sunvozertinib produces Phase III goods in EGFR exon 20 insertion NSCLC
Dizal Pharmaceutical (SSE: 688192) reported that sunvozertinib (Zegfrovy) cut the risk of progression or death by 35% versus platinum-doublet chemotherapy...
BeOne Medicines' zanubrutinib demonstrates superior progression-free survival in Phase III SEQUOIA CLL trial
BeOne Medicines (Nasdaq: ONC) reported 78-month follow-up data from the Phase III SEQUOIA trial at ASCO 2026, showing zanubrutinib (Brukinsa) maintained a...
Pfizer's lorlatinib achieves unprecedented seven-year progression-free survival in ALK-positive NSCLC
Pfizer (NYSE: PFE) reported seven-year follow-up data from the Phase III CROWN trial showing that 55% of previously untreated ALK-positive non-small cell...
Agios' tebapivat fails to meet advancement threshold in lower-risk myelodysplastic syndromes trial
Agios Pharmaceuticals (Nasdaq: AGIO) reported Thursday that tebapivat failed to meet its predefined advancement threshold in lower-risk myelodysplastic...
BMS posts Phase III data for mezigdomide showing 52% reduction in disease progression risk in r/r MM
Bristol Myers Squibb (NYSE: BMY) reported Phase III data from the SUCCESSOR-2 trial showing that mezigdomide combined with carfilzomib and dexamethasone cut...
TG Therapeutics' ublituximab-xiiy meets primary endpoint in Phase IIIb relapsing multiple sclerosis trial
TG Therapeutics (Nasdaq: TGTX) reported that its Phase III ENHANCE trial met its primary endpoint, demonstrating that a consolidated single 600 mg infusion...
D&D Pharmatech's GLP-1/glucagon dual agonist hits Phase II endpoints in MASH
D&D Pharmatech (Kosdaq: 347850) has reported 48-week histology data from its Phase II trial of zabopegdutide in metabolic dysfunction-associated...
The AllSci Brief
Systematic R&D and deal news. Daily.